Cagrilintide in people with obesity who stopped GLP-1 therapies due to gut side effects

You may qualify if

• Male or female (sex at birth)
• Age 18 years or above at the time of signing the informed consent
• History of documented treatment with GLP-1-RA medications with gastrointestinal (GI) adverse effects as the main reason for treatment discontinuation
• Not suitable for re-initiation of GLP-1-RA treatment based on medical history and investigator judgement
• Body mass index (BMI) greater than or equal to (≥) 30.0 kilograms per square meter (kg/m^2)

You can't join if

• Female who is pregnant, breast-feeding, or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive methods
• Treatment with GLP-1 receptor agonist or GLP-1-RA medication for any indication within 8 weeks before screening
• History of type 1 or type 2 diabetes
• Glycated haemoglobin (HbA1c) ≥ 6.5 percent (%) (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening
• Treatment with glucose-lowering agent(s) prescribed for the indication of diabetes or pre-diabetes within 90 days before screening
• Treatment with any medication prescribed for the indication of weight management within 8 weeks before screening